Form 4: Avanos Medical Executive Acquires Shares and Surrenders Shares for Tax Obligations
SEC Form 4 Filing
John Joseph Hurley, Principal Accounting Officer of Avanos Medical, Inc., reports acquisition of shares and surrender of shares to cover tax obligations related to vesting restricted share units.
Summary
- On March 6, 2024, John Joseph Hurley, Principal Accounting Officer of Avanos Medical, Inc., acquired 1,829 shares of common stock at $19.14 per share.
- The acquisition was related to time-based restricted share units (TRSUs) awarded under the company's 2021 Long Term Incentive Plan, as amended, vesting in three equal installments on March 6, 2025, March 6, 2026, and March 6, 2027.
- On the same day, Hurley surrendered 141 shares at $19 to cover tax withholding obligations upon the vesting of TRSUs awarded on March 6, 2023.
- Following these transactions, Hurley directly owns 6,645 shares of Avanos Medical, Inc.
- Hurley also beneficially owns 162 shares acquired on December 31, 2023 and 140 shares acquired on June 30, 2023 under the Issuer's Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The document reflects routine insider transactions, which are neither particularly positive nor negative. It's a neutral disclosure.
Positives
- The acquisition of shares by a company officer could be seen as a positive signal, indicating confidence in the company's future performance.
Negatives
- The surrender of shares to cover tax obligations is a neutral event and doesn't necessarily indicate a negative outlook.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their insiders.
- The transactions reported are typical for executives receiving stock-based compensation and managing their tax obligations.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 06/30/2023 | 140 shares acquired under the Issuer's Employee Stock Purchase Plan. |
| 03/06/2023 | Date of original TRSU award, vesting in installments. |
| 12/31/2023 | 162 shares acquired under the Issuer's Employee Stock Purchase Plan. |
| 03/06/2024 | Acquisition of 1,829 shares and surrender of 141 shares. |
| 03/06/2025 | First vesting date for TRSUs awarded on March 6, 2024 (1/3). |
| 03/06/2026 | Second vesting date for TRSUs awarded on March 6, 2024 (1/3). |
| 03/06/2027 | Final vesting date for TRSUs awarded on March 6, 2024 (1/3). |
| 03/07/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.